KNSA — Kiniksa Pharmaceuticals International, plc
$96.33
+$0.05 (+0.05%)
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Market Cap
$7.57B
Forward P/E
44.1x
52-Week Range
N/A
KNSA Price History
Revenue vs. Net Income
$678M
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$136M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
12.4%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
3.9x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
0.2%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+10.6%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
